Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

50

Revenue 2017

Levemir

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Levemir was produced by Novo Nordisk.

Novo Nordisk profits up 4%, buoyed by Victoza and Levemir

Novo Nordisk profits up 4%, buoyed by Victoza and Levemir The Danish pharma company's net profits rose 4% to DKK 20bn (about 2.7bn), driven by its established diabetes brands Victoza (liraglutide) and Levemir (insulin detemir). ... In the US, Levemir continues to perform well and with the approval of Xultophy

Novo Nordisk debuts diabetes combo in Mexico

Novo Nordisk debuts diabetes combo in Mexico acting insulin analogue Levemir (insulin detemir) to help manage the shortfall. ... For example, in Japan it has 20% market share 18 months after its launch despite competing in the market directly with Lantus and Levemir.

ADA: Novo says switching to Tresiba could reduce NHS costs

ADA: Novo says switching to Tresiba could reduce NHS costs The company claims that UK patients with diabetes who started taking Tresiba (insulin degludec) after experiencing problems with Novo's own Levemir (insulin detemir) or Sanofi's Lantus (insulin glargine) reported

Novo Nordisk will build $100m facility in Denmark

Novo Nordisk will build $100m facility in Denmark The setback delayed the drugs in the US by around two years and prompted a reshuffle of priorities at the Danish drugmaker, including a renewed focus on promotion of Levemir (insulin

Merck joins biosimilar Lantus race

Merck joins biosimilar Lantus race Insulin glargine biosimilars could prove disruptive to Lantus as, Tresiba and LY2605541 - as well as Novo Nordisk's $2bn-a-year long-acting insulin Levemir (insulin detemir) - as they are likely

[ Previous 5 results ] 1 2 3 4 5 6 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics